{"filings":[{"id":92792,"accession_number":"0001425450-26-000033","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics Corp. furnishes investor presentation for upcoming meetings; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company will use the attached investor presentation in upcoming analyst and investor meetings.","No specific financial updates, guidance changes, or business developments were included in the filing.","Presentation dated April 2026; full content not provided in the exhibit text.","Filing under Regulation FD; information is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92791,"accession_number":"0001425450-26-000032","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics Q1 revenue up 13% to $59.4M; lifts FY2026 guidance to $263-267M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $59.4M (13% YoY); US +11%, International +22%; Trauma & Deformity +14%, Scoliosis +13%.","Adjusted EBITDA of $2.2M vs. -$0.4M in Q1 2025; net loss unchanged at $10.7M (-$0.45 EPS).","Free cash flow usage improved 40% to -$5.0M from -$8.4M.","FY2026 revenue guidance raised to $263-267M (prior $262-266M); adj. EBITDA reiterated ~$25M.","Cash & equivalents $50.9M (down from $62.9M at Dec 31, 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":59362000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92790,"accession_number":"0001104659-26-038610","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"OrthoPediatrics adds $20M delayed draw term loan facility via credit agreement amendment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment creates $20M delayed draw term loan facility; draws allowed until June 30, 2027 in minimum $10M increments.","Interest at SOFR + 6.50% (floor 3.25%); company may elect 1.00% PIK; interest-only until August 5, 2029 maturity.","Company not required to draw; pays 1.00% upfront fee and 0.05% per annum ticking fee.","Lenders are funds managed by Braidwell LP; Wilmington Trust National Association continues as agent.","Facility supports disciplined liquidity management and flexible capital deployment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103924,"accession_number":"0001425450-26-000010","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics files Feb 2026 investor presentation with no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing furnishes an investor presentation dated February 2026 for upcoming analyst meetings.","Exhibit text provided is incomplete; no earnings, guidance, or operational metrics were included.","No changes to business outlook, capital allocation, or leadership were announced.","Company's common stock trades on Nasdaq under ticker KIDS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103923,"accession_number":"0001425450-26-000009","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics reports record 2025 revenue $236.3M (+15% YoY); Q4 first positive free cash flow $9.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record FY2025 revenue $236.3M, up 15% from $204.7M in 2024.","Q4 2025 revenue $61.6M (+17% YoY); net loss per share $0.43 vs $0.69.","Adjusted EBITDA FY2025 $14.8M vs $8.5M; Q4 adjusted EBITDA $4.8M vs $3.0M.","Generated $9.8M free cash flow in Q4, first positive FCF quarter; cash $62.9M.","FY2026 guidance: revenue $262-266M (11-13% growth), adjusted EBITDA ~$25M, breakeven cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":236348000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103922,"accession_number":"0001425450-26-000006","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics files investor presentation for upcoming meetings; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing discloses upcoming investor presentations using Exhibit 99.1, a 2026 investor presentation.","The exhibit is a cover slide with no specific financial or operational updates.","No new guidance, earnings, or material events are announced in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103921,"accession_number":"0001425450-26-000003","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics posts record FY2025 revenue $236.1M (+15% YoY); guides FY2026 revenue $262-266M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $61.3M (+16% YoY); domestic $48.4M (+13%), international $12.9M (+32%).","FY2025 free cash flow usage over 50% lower than FY2024; Q4 FCF $6-7M.","FY2026 revenue guidance $262-266M (11–13% growth); expects ~$25M Adjusted EBITDA.","Received EUMDR certification for Response Spine and trauma/deformity implants.","Helped 37,500 children in Q4; nearly 1.3 million since inception."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":236348000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120196,"accession_number":"0001425450-25-000112","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics files investor presentation for October 2025; no specific financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing under Item 7.01 for upcoming investor meetings; presentation slides furnished as Exhibit 99.1.","No earnings, guidance, or material corporate events disclosed in the filing.","Company executives scheduled to present to analysts and investors; presentation slides not publicly detailed.","Confidence is low due to absence of substantive new information in the attached exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120195,"accession_number":"0001425450-25-000111","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics Q3 revenue $61.2M (+12% YoY); adjusted EBITDA up 56% to $6.2M; raises FY2025 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $61.2M, +12% YoY (17% ex-7D capital); Trauma & Deformity +17%, Scoliosis +4%.","GAAP EPS -$0.50 vs -$0.34; non-GAAP EPS -$0.24 vs -$0.18; net loss $11.8M vs $7.9M.","Adjusted EBITDA $6.2M (+56% YoY); free cash flow usage improved to $3.4M from $11.6M.","FY2025 revenue guidance raised to $233.5-234.5M (+14-15%); adjusted EBITDA guidance reiterated $15-17M.","Recorded $2.3M restructuring charge and $2.3M intangible impairment (ApiFix, Telos, Medtech)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":174743000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120194,"accession_number":"0001425450-25-000108","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics preliminary Q3 rev $61.2M (+12% YoY); cuts FY guidance to $233.5-$234.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 net revenue $61.2M, up 12% YoY; domestic $48.7M (+14%), international $12.5M (+6%).","Revenue excluding 7D capital sales $60.7M, up 17% YoY; capital sales delayed late in quarter.","FY2025 revenue guidance lowered to $233.5-$234.5M from $237-$242M; growth 14-15% YoY.","Reiterated $15M set deployment and adjusted EBITDA guidance of $15-$17M.","Headwinds: delayed 7D capital orders and Latin/South America order timing variability."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":174743000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136770,"accession_number":"0001425450-25-000099","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OrthoPediatrics board member Schlotterback retires; Kelly Fischer appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terry Schlotterback resigned from Board effective Aug. 8, 2025, due to retirement; no disagreement.","Kelly Fischer (SVP & CFO of Cook Medical) appointed to fill vacancy, to serve until 2026 annual meeting.","Fischer appointed to Audit and Compensation committees; eligible for pro rata director compensation.","Schlotterback’s 10,900 unvested restricted shares will continue vesting per original schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136769,"accession_number":"0001425450-25-000093","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics files August 2025 investor presentation; no specific metrics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation filed as Exhibit 99.1 with no financial results or operational updates in the filing text.","Presentation date referenced as 'August 2025' but slides not reproduced; content not analyzable from provided materials.","No guidance change, earnings data, M&A, or leadership changes discussed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136768,"accession_number":"0001425450-25-000092","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics Q2 revenue hits record $61.1M (+16% YoY); raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $61.1M (+16% YoY); domestic up 17%, international up 12%.","Adjusted EBITDA $4.1M (+58% YoY); non-GAAP EPS improved to ($0.11) from ($0.23).","Raised FY2025 revenue guidance to $237-242M from $236-242M; reaffirmed adjusted EBITDA $15-17M.","Scoliosis revenue +35% to $18.5M; Trauma & Deformity +10% to $41.7M.","OPSB expanded with new clinics, entry into Ireland for first international operation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":113493000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136767,"accession_number":"0001425450-25-000090","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics expands specialty bracing into California, Ohio, Colorado, New York, and Ireland","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First OPSB clinic in California opens in Los Angeles market, providing access to millions of potential patients.","New clinic opens in Dayton, OH within Dayton Children's Hospital, expanding Ohio territory.","Added clinics and clinicians to cover Denver, CO territory; New York operation adds multiple locations at major children's hospitals.","Ireland becomes OPSB's first international market, complementing existing implant business in country's largest pediatric hospital.","Management says expansion is slightly ahead of planned entry into 4 new target markets for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153993,"accession_number":"0001425450-25-000059","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OrthoPediatrics stockholders elect directors, approve say-on-pay and auditor ratification at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected four directors: Fred L. Hite (17.1M for), Bryan W. Hughes (18.0M for), Samuel D. Riccitelli (11.5M for), Mark C. Throdahl (16.3M for); note significant withheld votes for Riccitelli (7.7M).","Advisory approval of named executive officer compensation passed with 19.0M for, 0.15M against, 0.06M abstain.","Ratified Deloitte & Touche LLP as independent auditor for fiscal year 2025 with 19.9M for, 0.03M against, 0.001M abstain.","Total broker non-votes were 695,511 on director elections and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153992,"accession_number":"0001425450-25-000056","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"OrthoPediatrics amends Medtech Concepts acquisition; remaining $3.75M due in stock instead of cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First Amendment replaces three $1.25M cash earn-outs with unregistered common stock installments.","Stock issued on 2nd, 3rd, and 4th anniversaries of May 2023 closing; issuer relies on Section 4(a)(2) exemption.","Share count calculated using 30-day VWAP ending two business days before each anniversary date.","Payment to Kevin Unger contingent on his continuing service; total stock value approximately $3.75M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153991,"accession_number":"0001425450-25-000048","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics files May 2025 investor presentation; no material new details","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1 for upcoming analyst and investor meetings.","No earnings, guidance, or key metrics referenced in the filing or exhibit.","Confidence low because exhibit content is limited to a title slide only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153990,"accession_number":"0001425450-25-000047","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics Q1 revenue $52.4M (+17% YoY); raises FY2025 guidance to $236-242M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 revenue $52.4M (+17% YoY); U.S. revenue $40.9M (+19%), international $11.5M (+11%).","Net loss $10.7M ($0.46 per share) vs. $7.8M ($0.34) in Q1 2024; adjusted EBITDA loss improved to ($0.4M) from ($1.1M).","FY2025 revenue guidance raised to $236M-$242M (15-18% growth); adjusted EBITDA guidance reiterated at $15-17M.","Scoliosis revenue grew 34% to $13.7M; launched VerteGlide system for Early Onset Scoliosis.","Cash, equivalents and restricted cash $60.8M at quarter end vs. $70.8M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":52411000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172634,"accession_number":"0001425450-25-000017","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics files investor presentation with no new material information","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing announces upcoming investor presentations using Exhibit 99.1.","Exhibit 99.1 is a presentation cover slide with no financial or operational data.","No earnings, guidance, or material events disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172633,"accession_number":"0001425450-25-000012","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics reports record FY2024 revenue of $204.7M, up 38% YoY; Q4 adjusted EBITDA doubles to $3.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue $204.7M, up 38% from $148.7M in 2023; Q4 revenue $52.7M, up 40% YoY.","Full year adjusted EBITDA $8.5M vs $5.0M in 2023; Q4 adjusted EBITDA $3.0M, more than double $1.3M.","Net loss widened to $37.8M in 2024 from $21.0M in 2023; Q4 net loss $16.1M ($0.69/sh) vs $6.7M ($0.29/sh).","FY2025 guidance: revenue $235-242M (15-18% growth), adjusted EBITDA $15-17M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172632,"accession_number":"0001425450-25-000009","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics files investor presentation for upcoming meetings, no financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed a Regulation FD disclosure (Item 7.01) regarding upcoming investor and analyst presentations.","Exhibit 99.1 attached is a 2025 investor presentation intended for use by executive officers.","Filing does not include specific financial results, guidance, or material events beyond the presentation availability.","No substantive operational or financial data provided in the filing or appended exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172631,"accession_number":"0001425450-25-000005","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics reports record FY2024 revenue of $204.7M (+38% YoY), issues 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited FY2024 revenue $204.7M, up 38% from $148.7M in 2023.","Q4 2024 revenue $52.7M (+40% YoY); domestic Q4 $42.9M (+52%), international $9.8M (+5%).","2025 revenue guidance $235-242M (15-18% growth); adjusted EBITDA $15-17M.","Over 34,000 children helped in Q4; cumulative >1.1 million since inception.","Annual set deployment ~$15M in 2025; full results due in early March."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":204727000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189637,"accession_number":"0001425450-24-000096","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics furnishes Nov 2024 investor presentation; no specific financial data disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Executive officers will use the presentation in upcoming meetings with analysts and investors.","The presentation was furnished under Regulation FD; no specific operational or financial updates provided in the exhibit.","No material changes to guidance, earnings, or business strategy were disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189636,"accession_number":"0001425450-24-000090","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics Q3 record revenue $54.6M (+37% YoY); raises FY guidance to $202-204M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $54.6M (+37% YoY); domestic up 45%, international up 12%.","Net loss $7.9M ($0.34/shr) vs $4.6M ($0.20) YoY; $3.2M one-time refinancing expense.","Adjusted EBITDA $4.0M vs $3.6M in Q3 2023; gross margin 73% vs 77%.","Raised FY 2024 revenue guidance to $202-204M from $200-203M; reaffirmed Adj. EBITDA $8-9M.","Helped record >33,000 children (+50% YoY); Trauma & Deformity +31%, Scoliosis +52%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":152060000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189635,"accession_number":"0001425450-24-000087","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"OrthoPediatrics inks new employment pacts with CEO, CFO, and three other NEOs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Bailey base salary $550k; CFO Hite $501k; Odle/Gerritzen $368k; Hauser $400k.","Severance: 30 months base + 2.5x avg bonus if terminated w/o cause or for good reason.","Three-year initial term, auto-renew one-year; non-compete extends 30 months post-termination.","Change-of-control triggers severance if employment terminated or title changed within 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206132,"accession_number":"0001425450-24-000085","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics holds Investor Day on Sept 12, 2024; notes >1M kids helped","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor Day presentation on September 12, 2024 with investor and analyst meetings.","Company reports over 1,000,000 children helped since inception.","Presentation to be used in upcoming investor meetings throughout September 2024.","No specific financial data, guidance, or material operational metrics disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206131,"accession_number":"0001104659-24-088333","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"OrthoPediatrics closes $25M term loan and $50M convertible notes issuance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$25M term loan from Braidwell LP funded on August 12, 2024.","Issued $50M aggregate principal of 4.75% Convertible Senior Notes due Feb 15, 2030 to Braidwell.","Initial conversion rate of 33.8294 shares per $1,000 principal, maximum 1,691,470 shares issuable.","Notes issued under Section 4(a)(2) in a private placement; resale restricted to QIBs for 12 months.","Transactions were previously announced on August 5, 2024; closing occurred on August 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206130,"accession_number":"0001425450-24-000081","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics provides investor presentation for August 2024; details not disclosed in filing.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished an investor presentation dated August 2024 for use in meetings with investors and analysts.","No specific financial or operational metrics were included in the filed exhibit text.","The presentation is intended for general corporate updates; no material new guidance or events were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206129,"accession_number":"0001425450-24-000077","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics reports record Q2 revenue up 33% to $52.8M; net loss widens to $6.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $52.8M (+33% YoY); U.S. +39%, Intl +16%. Trauma & Deformity +37%, Scoliosis +26%.","Net loss $6.0M ($0.26/share) vs $2.9M loss ($0.13) in Q2 2023; Adjusted EBITDA $2.6M vs $2.3M.","Reaffirmed FY2024 revenue guidance $200M-$203M (34-36% growth); EBITDA guidance $8M-$9M.","Announced $100M financing (term loan + convertible notes) from Braidwell LP; expects to close Aug 12, 2024.","Approved $5M stock buyback; cash $30.9M (down from $82.3M Dec 2023) due to $5.5M one-time payments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":97487000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206128,"accession_number":"0001104659-24-085842","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"OrthoPediatrics secures up to $100M from Braidwell: $25M term loan + $25M delayed draw + $50M convertible notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term loan at SOFR + 6.50% (PIK option adds 1.00%), interest-only until August 2029 maturity.","Convertible notes: $50M at 4.75% interest, due Feb 2030, convertible at ~$40.98/share (30% premium to VWAP).","Proceeds used to repay ~$10M debt, pay ~$6.5M transaction fees, fund up to $5M stock repurchase, and general corporate purposes.","Post-closing pro forma cash, cash equivalents & restricted cash would be ~$90M (excluding delayed draw); financial covenants require 25% cash collateral and minimum net product sales.","Stock repurchase of up to $5M approved; represents ~169K shares (~0.7% of outstanding) at $29.56 close on Aug 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223175,"accession_number":"0001425450-24-000038","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OrthoPediatrics stockholders elect directors, approve compensation and incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David R. Bailey, Marie C. Infante, Jimmy D. McDonald elected as directors with 91.1%, 63.8%, 71.4% of votes cast respectively.","Advisory vote on executive compensation approved with 98.7% of votes cast (19.4M for).","OrthoPediatrics Corp. 2024 Incentive Award Plan approved with 93.5% of votes cast (18.4M for).","Ratification of Deloitte & Touche as independent auditor for FY2024 approved with 99.3% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223174,"accession_number":"0001104659-24-065338","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"OrthoPediatrics stockholders approve 2024 Incentive Award Plan, replacing 2017 plan","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Board adopted the 2024 Incentive Award Plan on Feb 29, 2024, with stockholder approval obtained on May 24, 2024.","Plan serves as successor to the 2017 Incentive Award Plan; no further awards will be granted under the 2017 Plan.","Material terms described in the definitive proxy statement filed April 8, 2024, incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223173,"accession_number":"0001425450-24-000036","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OrthoPediatrics files investor presentation for May 2024 meetings; no new material information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished an investor presentation (Exhibit 99.1) for upcoming analyst and investor meetings.","Presentation does not contain new financial guidance, earnings results, or material non-public information.","Filing is a routine Regulation FD disclosure; no specific numbers or events provided in the exhibit text.","Ticker: KIDS; date of report: May 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223172,"accession_number":"0001425450-24-000031","cik":1425450,"company_name":"ORTHOPEDIATRICS CORP","ticker":"KIDS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OrthoPediatrics Q1 revenue up 41% to $44.7M; raises FY 2024 guidance to $200-203M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $44.7M (+41% YoY); U.S. +44%, international +33%.","Net loss $7.8M ($0.34 loss per share) vs $6.8M ($0.30) a year ago.","Adjusted EBITDA loss improved to $1.1M from $2.1M in Q1 2023.","Raised full-year 2024 revenue guidance to $200-203M from prior $197-200M.","Boston O&P acquisition contributed; cash & restricted cash $49.7M at March 31."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":44685000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":450938573.45222217,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}